September 12th 2024
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Immunotherapy Will Play a Critical Role in Osteosarcoma Treatment, Expert Says
December 29th 2016Nancy Gordon, MD, speaks about her osteosarcoma research, the next steps following the findings of the study, and what she envisions for the treatment landscape of osteosarcoma over the next decade.
Read More
New Agents, Targets Continue to Emerge in Sarcoma, Cementing Role for Immunotherapy
November 29th 2016Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.
Read More
Limb Function Not Improved by Lower Volume Radiation for Extremity STS
November 19th 2016A lower dose of radiation therapy following surgery did not improve limb function and was not found to be non-inferior compared with standard dose radiation 2 years post procedure in patients extremity soft tissue sarcoma.
Read More
TRC105 Plus Pazopanib Shows Promise in Advanced Angiosarcoma
November 13th 2016TRC105, an endoglin antibody, combined with pazopanib showed promising anti-tumor activity in patients with advanced angiosarcoma, warranting the initiation of a phase III study to explore the combination further.<br />
Read More
Radiomics Could Play Important Predictive Role in Patient Outcomes in Sarcoma
November 12th 2016Though surgical resection and radiation therapy remain at the forefront of the treatment for localized disease, accurately predicting outcomes for individual patients remains a challenge, which radiomics, an emerging research field, hopes to alleviate.
Read More
Model Suggests Olaratumab May Be Effective in Pediatric Sarcoma
November 12th 2016Olaratumab displayed anti-tumor activity both as a single-agent and in concert with standard of care chemotherapy in a study using human pediatric sarcoma cell-derived models and in human sarcoma cell transfected mice.
Read More
Pembrolizumab Plus Cyclophosphamide Shows Limited Benefit in Diverse Types of Sarcoma
November 12th 2016Pembrolizumab plus low dose metronomic cyclophosphamide demonstrated limited patient benefit in adult patients with diverse types of unresectable locally advanced or metastatic sarcoma.<br />
Read More
Nivolumab/Pazopanib Combo Shows Promise in Relapsed Sarcoma
November 12th 2016Clinical benefit, including partial response and stable disease, was observed in 11 of 20 patients with relapsed metastatic sarcoma following nivolumab treatment that was administered either alone or in combination with pazopanib.
Read More
Expert Discusses Pembrolizumab Potential in Sarcoma
November 12th 2016Updated results of the multicenter phase II study SARC028 demonstrate both a favorable safety profile as well as encouraging efficacy for the use pembrolizumab (Keytruda) as a treatment for patients with advanced sarcomas.
Read More
Pembrolizumab Demonstrates Anti-Tumor Activity in Sarcoma Subtypes
November 11th 2016Treatment with pembrolizumab, an immunotherapeutic agent approved in melanoma, lung, and head and neck cancer, and which is undergoing investigation in several other cancer types, reduced the size of tumors in patients with a specific soft tissue sarcoma.
Read More
Risk of Local Recurrence Varies Across Sarcoma Histotypes With Adjuvant/Neoadjuvant Therapy
November 11th 2016Adjuvant chemotherapy was found to decrease the rates of local recurrence in some subtypes of extremity soft tissue sarcoma; however, the use of adjuvant/neoadjuvant therapy did not impact overall survival.
Read More
Expert Highlights Factors Influencing Local Control in Ewing Sarcoma
November 11th 2016 <br /> Local recurrence is associated with very poor prognosis in patients with Ewing sarcoma. Researchers are seeking to identify the factors associated with local recurrence in patients undergoing multimodal treatment.
Read More